Education
About Us
Working with TipRanks
Follow Us
Pulse Biosciences (PLSE)
NASDAQ:PLSE
PLSE Stock Chart & Stats
$18.58
-$0.27(-1.46%)
At close: 4:00 PM EST
$18.58
-$0.27(-1.46%)
Day’s Range― - ―
52-Week Range$12.56 - $26.30
Previous CloseN/A
Volume31.18K
Average Volume (3M)189.63K
Market Cap
$1.26B
Enterprise Value$1.19B
Total Cash (Recent Filing)$80.73M
Total Debt (Recent Filing)$7.53M
Price to Earnings (P/E)―
Beta1.57
Next Earnings
May 07, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding67,989,075
10 Day Avg. Volume222,519
30 Day Avg. Volume189,626
Financial Highlights & Ratios
PEG Ratio-0.73
Price to Book (P/B)11.47
Price to Sales (P/S)2643.82
P/FCF Ratio-17.00
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue3.39K
Enterprise Value/Gross Profit-1.66K
Enterprise Value/Ebitda-16.27
Forecast
1Y Price Target
$30.00Price Target Upside61.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.33
Revenue Forecast (FY)$3.40M
Bulls Say, Bears Say
Bulls Say
Regulatory Progress (IDE Approvals)Securing multiple IDE approvals and planned pivotal enrollments materially de-risks the regulatory pathway for core EP and surgical indications. These approvals enable U.S. pivotal data generation needed for broader market access and reimbursement discussions, supporting multi‑quarter commercial milestones and durable expansion of addressable markets.
Compelling Clinical EfficacyRobust feasibility results showing high procedural success and durable 12‑month freedom from arrhythmia strengthen the clinical value proposition. Durable clinical differentiation versus legacy ablation could drive physician adoption, hospital procurement decisions, and payer conversations over several quarters as pivotal studies replicate early findings.
Expanding Patent EstateA rapidly growing IP portfolio creates barriers to entry around nsPFA technology, protecting product differentiation and licensing optionality. A broad patent estate supports long‑term competitive advantage, potential royalty or partnership leverage, and helps sustain product pricing and margins as commercial scale is pursued.
Bears Say
High Cash Burn And LossesAccelerating operating cash outflows and widening net losses materially shorten runway absent revenue scale or financing. Persistent negative free cash flow pressures strategic flexibility, may force prioritization of programs, and increases reliance on external funding over the next several quarters to sustain pivotal trials and commercialization.
Funding And Dilution RiskManagement’s use of shelf and ATM facilities signals ready access to equity but also a tangible dilution pathway if capital is drawn. Given ongoing negative cash flow and upcoming trial/commercial investments, reliance on equity markets or partnerships is likely within the planning horizon, affecting long‑term capital structure and shareholder dilution risk.
Very Limited Current Commercial TractionNominal product revenue and near‑zero gross margin indicate commercialization is still embryonic. Broader scale depends on additional regulatory clearances, reimbursement progress and expanded distribution; until these structural enablers arrive, recurring consumable economics and margin expansion remain uncertain over multiple quarters.
Pulse Biosciences News
PLSE FAQ
What was Pulse Biosciences’s price range in the past 12 months?
Pulse Biosciences lowest stock price was $12.56 and its highest was $26.30 in the past 12 months.
What is Pulse Biosciences’s market cap?
Pulse Biosciences’s market cap is $1.26B.
When is Pulse Biosciences’s upcoming earnings report date?
Pulse Biosciences’s upcoming earnings report date is May 07, 2026 which is in 61 days.
How were Pulse Biosciences’s earnings last quarter?
Pulse Biosciences released its earnings results on Feb 19, 2026. The company reported -$0.183 earnings per share for the quarter, beating the consensus estimate of -$0.265 by $0.082.
Is Pulse Biosciences overvalued?
According to Wall Street analysts Pulse Biosciences’s price is currently Undervalued.
Does Pulse Biosciences pay dividends?
Pulse Biosciences does not currently pay dividends.
What is Pulse Biosciences’s EPS estimate?
Pulse Biosciences’s EPS estimate is -0.27.
How many shares outstanding does Pulse Biosciences have?
Pulse Biosciences has 67,989,075 shares outstanding.
What happened to Pulse Biosciences’s price movement after its last earnings report?
Pulse Biosciences reported an EPS of -$0.183 in its last earnings report, beating expectations of -$0.265. Following the earnings report the stock price went down -14.593%.
Which hedge fund is a major shareholder of Pulse Biosciences?
Currently, no hedge funds are holding shares in PLSE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pulse Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$30.00 (61.46% Upside)
$30.00 (61.46% Upside)
Blogger Sentiment
Bullish
PLSE Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 11.6K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.46%
12-Months-Change
Fundamentals
Return on Equity
-86.99%
Trailing 12-Months
Asset Growth
16.89%
Trailing 12-Months
Company Description
Pulse Biosciences
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
PLSE Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed strong clinical and technology progress—IDE approvals, compelling early efficacy data with high 12‑month success rates, rapid procedure times, and substantial IP expansion—which materially de-risks key scientific and regulatory milestones. However, the financial picture remains early-stage: product revenue is still nominal, gross margin was effectively negligible in the quarter, operating losses persist, cash reserves declined substantially year-over-year, and broader commercialization hinges on additional regulatory clearances and reimbursement processes that may take multiple quarters. Overall, the narrative balances important clinical/strategic momentum against clear near-term financial and commercialization constraints.View all PLSE earnings summariesPLSE Stock 12 Month Forecast
Average Price Target
$30.00
▲(61.46% Upside)
Technical Analysis
Ownership Overview
73.58% Insiders
2.29% Mutual Funds
1.49% Other Institutional Investors
19.90% Public Companies and
Individual Investors